Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control

Diabetes

Volumn 58, Issue 3, 2009, Pages 710-717

  Mitsuishi, Masanori ^a   Miyashita, Kazutoshi ^a   Muraki, Ayako ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR 1; ANGIOTENSIN 2 RECEPTOR 2; ANGIOTENSIN II; REACTIVE OXYGEN METABOLITE; RECEPTOR SUBTYPE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; MITOCHONDRIAL DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DEGRADATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HORMONE ACTION; LIPID METABOLISM; LIPID OXIDATION; MALE; METABOLIC REGULATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MUSCLE LEVEL; MUSCLE MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REGULATORY MECHANISM; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; CALORIMETRY; CELL LINE; CELL MEMBRANE POTENTIAL; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION; GENETICS; GLUCOSE TOLERANCE TEST; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANGIOTENSIN II; ANIMALS; CALORIMETRY, INDIRECT; CELL LINE; DNA, MITOCHONDRIAL; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MITOCHONDRIA, MUSCLE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA INTERFERENCE;

EID: 62749137411     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0949     Document Type: Article

References (40)

1. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-2950, 2002
2. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE: Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54:8-14, 2005
3. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671, 2004
4. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466-8471, 2003
5. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273, 2003
6. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI: Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115:3587-3593, 2005
7. Petersen KF, Dufour S, Shulman GI: Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2:e233, 2005
8. Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Science 307:384-387, 2005
9. Kim JA, Wei Y, Sowers JR: Role of mitochondrial dysfunction in insulin resistance. Circ Res 102:401-414, 2008
10. Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33:613-621,1999
11. Stump CS, Hamilton MT, Sowers JR: Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 81:796-806,2006
12. Perkins JM, Davis SN: The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes 15:147-152, 2008
13. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME: Why blockade of the renin-angiotensin system reduces the incidence of new- onset diabetes. J Hypertens 23:463-473, 2005
14. Leiter LA, Lewanczuk RZ: Of the renin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18:121-128, 2005
15. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS: Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am JPhysiol Endocrinol Metab 294:E345-E351, 2008
16. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS: Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 28:35137-35146, 2006
17. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158-2169, 1997
18. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51:1699-1707, 2002
19. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, Chiwata T, Miyamoto Y, Yoshimasa Y, Fukamizu A, Horiuchi M, Hirata Y, Ogawa Y: Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146:3481-3489, 2005
20. cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem Biophys Res Commun 367:840-845, 2008
21. Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199, 1991
22. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K: Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation 106:1722-1728, 2002
23. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509,1957
24. Bass A, Brdiczka D, Eyer P, Hofer S, Pette D: Metabolic differentiation of distinct muscle types at the level of enzymatic organization. Eur J Bio-chem 10:198-206, 1969
25. Shadel GS: Expression and maintenance of mitochondrial DNA: new insights into human disease pathology. Am J Pathol 172:1445-1456, 2008
26. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M:Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55:478-488, 2006
27. Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Man- darino L, Ravussin E, Smith SR: Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 4:75-87, 2006
28. Kim I, Rodriguez-Enriquez S, Lemasters JJ: Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 462:245-253, 2007
29. de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Inserra F: Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am J Physiol Regul Integr Comp Physiol 290:R1616-R1625, 2006
30. de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG: Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 17:1096-1098, 2003
31. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M: Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43:1003-1010, 2004
32. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983-988, 1997
33. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600-1606, 1999
34. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
35. Kraegen EW, Cooney GJ: Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 19:235-241, 2008
36. Kelley DE, Goodpaster B, Wing RR, Simoneau JA: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 277:E1130-E1141, 1999
37. Befroy DE, Petersen KF, Dufour S, Mason GF, de Graaf RA, Rothman DL, Shulman GI: Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 56:13761381, 2007
38. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P: Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 26:1913-1923, 2007
39. Civitarese AE, Smith SR, Ravussin E: Diet, energy metabolism and mitochondrial biogenesis. Curr Opin Clin Nutr Metab Care 10:679-687,2007
40. Schrauwen-Hinderling VB, Roden M, Kooi ME, Hesselink MK, Schrauwen P: Muscular mitochondrial dysfunction and type 2 diabetes mellitus. Curr Opin Clin Nutr Metab Care 10:698-703, 2007